UPDATE: Stifel Upgrades Centene (CNC) to Buy

Stifel upgraded Centene (NYSE: CNC) from Hold to Buy with a price target of $75, implying 25% upside. Analyst Thomas A. Carrol highlighted attractive valuation and visibility on outlook.

"Centene has successfully closed the Health Net deal, re-established its outlook, and is trading at very attractive levels, in our opinion. We believe Centene (CNC) is well positioned to better manage its current business – including Health Net (HNT) – and continue to win its fair share of the sizable growth opportunity in Medicaid, strategic Medicare Advantage markets, programs at the confluence of both Medicare and Medicaid, and growing health insurance exchange marketplace," said the analyst.

For an analyst ratings summary and ratings history on Centene click here. For more ratings news on Centene click here.

Shares of Centene closed at $60.17 yesterday.

You May Also Be Interested In

• MarineMax (HZO) PT Lowered to $35 at Stifel
• Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
• Comcast Corp (CMCSA) PT Lowered to $48 at Pivotal Research